Clinigen Group acquires US rights to Proleukin from Novartis.

Clinigen Group plc has signed an agreement with Novartis to acquire the US rights to Proleukin (aldesleukin, human recombinant interleukin-2) for up to $210 million in cash, consisting of an upfront and deferred payments along with future sales related milestones. Clinigen already owns the rights to Proleukin outside the US, which it acquired in July 2018.

Highlights; Proleukin is indicated for metastatic melanoma and metastatic renal cell carcinoma in the US. Clinigen will be the exclusive global owner of the licensed version of this drug. Currently being used in around 80 active studies within the US across multiple disease areas. Has the potential to become an integral part of cancer combination therapies. Total consideration: up to $210 million for US rights to Proleukin. Initial $120 million payable. $60 million deferred consideration over the 12 months following completion A further $30 million consideration based on sales milestones In the year to 30 June 2018, in the US, Proleukin made revenue of $60.0 million according to IQvia (IMS).